Senti Bio price target lowered to $7 from $8 at Chardan

Chardan analyst Geulah Livshits lowered the firm’s price target on Senti Bio to $7 from $8 and keeps a Buy rating on the shares. The company reported Q4 results and reiterated upcoming catalysts for 2023, the analyst tells investors in a research note. Although Senti is preparing its Investigational New package and advancing toward the clinic, its cash runway remains an overhang and may not be sufficient to see the company through meaningful clinical data on SENTI-202, the analyst tells investors in a research note. The firm "conservatively" models dilution from a $50M equity offering in 2023.